In a comprehensive, within-subjects, placebo-controlled design, we acquired multimodal neuroimaging [i.e., EEG-fMRI (electroencephalography-functional MRI)] data to assess the effects of intravenous (IV) N,N-Dimethyltryptamine (DMT) on brain function in 20 healthy volunteers.

Functional MRI was also used to record the changes in brain activity during the DMT experience. Results obtained using this imaging modality shows us how DMT alters the interaction between key brain networks, and enables a comparison to previously obtained results from our psilocybin and LSD studies.

Mar 21, 2023 · Volunteers received a high dose of DMT (20mg, given intravenously), while simultaneously undergoing two types of brain imaging: functional magnetic resonance imaging (fMRI) and electroencephalography (EEG).

Mar 20, 2023 · Volunteers received a high dose of DMT (20mg, given intravenously), while simultaneously undergoing two types of brain imaging: functional magnetic resonance imaging (fMRI) and...

Mar 20, 2023 · In a comprehensive, within-subjects, place-bo-controlled design, we acquired multimodal neuroimaging [i.e., EEG-fMRI (elec-troencephalography-functional MRI)] data to assess the efects of intravenous (IV) N,N-Dimethyltryptamine (DMT) on brain function in 20 healthy volunteers.

Oct 29, 2024 · Resting-state functional Magnetic Resonance Imaging (rs-fMRI) can be used to detect changes in brain connectivity during psychedelic-induced states.

Among pwMS on injectable or oral DMT, imaging more CNS locations increased the odds of switching DMT after adjusting for age and relapse incidence. For pwMS on high-efficacy infusible DMTs, MRI did not change the odds of switching DMT but remains essential for safety monitoring.

Mar 22, 2023 · The study’s participants received a high dose of DMT (20mg, given intravenously), while simultaneously undergoing two types of brain imaging: functional magnetic resonance imaging (fMRI) and electroencephalography (EEG).

Sep 24, 2024 · This study provides Class III evidence that clinically stable patients with MS on low-/moderate-efficacy DMT with ≥3 new T2L on MRI who escalate DMT have a reduced risk of relapse and Expanded Disability Status Scale progression.

In a comprehensive, within-subjects, placebo-controlled design, we acquired multimodal neuroimaging [i.e., EEG-fMRI (electroencephalography-functional MRI)] data to assess the effects of intravenous (IV) N,N-Dimethyltryptamine (DMT) on brain function in 20 healthy volunteers.